Asthma management is very personalized. Find out what goes into to an asthma action plan and how medications are prescribed ...

YCT-529, a hormone-free male birth control pill, has shown high effectiveness in animals and is now in human trials, marking ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, discusses the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics and ...

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, ...

He holds a Bachelor of Science in Pharmacy from the University of Connecticut and is a registered pharmacist. Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use beyond acute pain management.

While the FDA has approved over 20 different categories of contraceptives, only two are available for men to prevent ...

Leveraging Commercial Data Infrastructure in Clinical Drug Development is the greatest connectivity we can have in the ...

Dr. Sepp-Lorenzino brings to AskBio over 30 years of executive, academic, and Board experience; Other Board positi ...

At the AMCP 2025 annual meeting, Sean Shirk, Pharm.D., stressed the need for payers to stay informed and engaged with legislation to sustain site-of-service efforts despite growing restrictions.

A groundbreaking male birth control pill, YCT529, is being developed by researchers at the University of Minnesota in partnership with Columbia University. This hormone-free option could revolutionize ...